Avelumab (Bavencio)
Immunotherapy · Approved since 2017
Description
Avelumab is a fully human monoclonal antibody immunotherapy that blocks the PD-L1 (programmed death-ligand 1) pathway to enhance anti-tumor immune responses. In colorectal cancer treatment, avelumab is used in combination with other agents such as cetuximab for rechallenge strategies in RAS wild-type metastatic disease and with 5-FU based chemotherapy for adjuvant treatment of stage 3 MSI-high or POLE mutant colon cancer. The drug has shown particular promise in microsatellite instability-high (MSI-H) colorectal cancers, which are more responsive to immune checkpoint inhibition.
Mechanism of Action
Avelumab binds specifically to PD-L1 and blocks its interaction with PD-1 receptors on T-cells, preventing the tumor from suppressing immune system activation. By inhibiting this immune checkpoint pathway, avelumab allows cytotoxic T-lymphocytes to maintain their anti-tumor activity and promotes sustained immune-mediated tumor cell destruction.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Bavencio |
| Category | Immunotherapy |
 Status | FDA Approved |
 EMA Status | EMA Approved |
 Spain Access | Hospital use off-label in CRC |
| Administration | IV |
| Year Approved | 2017 |
| Clinical Trials | 16 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.